


Portable Sleep Testing in Hospitalized Patients

Rami Khayat, MD

Heart Failure AND Public Health

- ≈ 6 million Americans with heart failure (>2% population)
- 20 million people with asymptomatic cardiac impairment
- 400,000 - 700,000 new cases diagnosed each year
- Most frequent cause of hospitalization in patients older than 65 years
- > 1.1 million heart failure hospitalizations annually

Redfield et al. circulation 1998 And AHA Fact book




Impact of Heart Failure on Public Health

- Heart failure causes or contributes to 250,000 deaths/year
- 1-Year mortality rate is about 10-15%
- 5-Year mortality rate approaches 50%
- 25% readmission rate at 1 month; 50% at 6 months
- > \$18 billion in annual direct costs
- **Despite current therapies and disease management approaches, the rate of heart failure hospitalization and mortality remains unacceptably high**

4

Impact of Heart Failure on Public Health


US Heart Failure Population
5.7 Million









Roger et al Circulation 2011
Ovdenburg et al Eur J Heart Fail 2007



- 83% of all heart failure patients will be hospitalized once and 43% at least 4 times.
- In 2010, there were 1.023 million admissions with HF in the US, essentially unchanged from 2001.
- By 2030, the total cost of HF will increase by 120% to \$ 70 billion from 2013 estimated cost of \$32 billion.
- AHA Heart Disease and Stroke Statistics 2013

Sleep Disordered Breathing (SDB)









Characteristics of ADHF Patients by SDB Status

	OSA Mean (SE)	CSA Mean (SE)	Negative Mean (SE)	Negatives vs. OSA P value	Negative vs. CSA P value	CSA vs. OSA P value
Age	60 (0.9)	58 (1.8)	56 (1.6)	0.03	0.37	0.40
Male	69% (3%)	75% (5%)	38% (5%)	0.0001	0.0001	0.30
Ischemic	62% (3%)	64% (6%)	44% (5%)	0.003	0.01	0.82
Dilated	23% (3%)	14% (4%)	35% (6%)	0.02	0.001	0.11
Others	15% (2%)	22% (5%)	21% (4%)	0.22	0.80	0.16
LVEF	34 (1.2)	27 (1.7)	38 (1.8)	0.06	0.0001	0.0008
BMI	33 (0.6)	29 (0.9)	31 (0.8)	0.03	0.12	0.0001
LVEDD	57 (1.1)	63 (1.6)	54 (1.2)	0.14	0.0001	0.0037
BNP	746 (66)	1341 (161)	873 (130)	0.35	0.02	0.001
A-fib	39% (3%)	32% (6%)	28% (5%)	0.06	0.57	0.31



Predictors of SDB in all patients with ADHF

Variable Names	Pearson Correlation Coefficients	Number of Patients	95% Confidence Limits
AHI with EF	-0.10	370	(-0.20, 0.00)
AHI with LVEDD	0.19	281	(0.07, 0.30)
AHI with BMI	0.17	393	(0.07, 0.26)
AHI with A-Fib	-0.02	394	(-0.12, 0.08)
AHI with Age	0.02	395	(-0.08, 0.12)
AHI with BNP	0.004	294	(-0.11, 0.12)

Predictors of AHI in all patients with ADHF and SDB


Variable Names	Pearson Correlation Coefficients	Number of Patients	95% Confidence Limits
AHI with EF	-0.01	279	(-0.13, 0.11)
AHI with LVEDD	0.15	212	(0.01, 0.28)
AHI with BMI	0.18	298	(0.07, 0.29)
AHI with Age	-0.06	298	(-0.17, 0.05)
AHI with BNP	-0.006	231	(-0.13, 0.12)


Predictors of severity of OSA

Variable Names	Pearson Correlation Coefficients	Number of Patients	95% Confidence Limits
AHI with EF	0.07	212	(-0.07, 0.20)
AHI with LVEDD	0.11	161	(-0.05, 0.26)
AHI with BMI	0.30	226	(0.17, 0.41)
AHI with A-Fib	-0.09	225	(-0.22, 0.04)
AHI with Age	-0.01	226	(-0.14, 0.12)
AHI with BNP	-0.07	174	(-0.22, 0.08)

Predictors of severity of CSA

Variable Names	Pearson Correlation Coefficients	Number of Patients	95% Confidence Limits
AHI with EF	-0.08	67	(-0.32, 0.16)
AHI with LVEDD	0.09	51	(-0.19, 0.36)
AHI with BMI	0.39	72	(0.19, 0.27)
AHI with A-Fib	-0.05	72	(-0.28, 0.19)
AHI with Age	-0.16	72	(-0.38, 0.07)
AHI with BNP	-0.05	57	(-0.31, 0.21)





Persistence of SDB and validation of the Inpatient Testing

20

Comparison of AHI between the in-hospital study and the polysomnography in the validated OSA and CSA patients

	PSG AHI	Inpatient AHI	Difference between PSG AHI and Inpatient AHI	95% CI for the Difference
	Mean (SE) (N)	Mean (SE) (N)		
OSA	41.7 (3.9) (62)	37.4 (2.5) (62)	4.3	-1.1, 9.6
CSA	36.4 (7.2) (12)	49.1(5.9) (12)	-12.7	-29.9, 4.5

Khayat et al JCF-2009



Comparison of Distribution of Cardiac readmissions in 6 months between CSA and no SDB Patients

Note the higher percent of patients readmitted for each count in the CSA

Khayat et al JCF 2012



Negative binomial models for count of readmissions within 6 months- ADHF patients with HFrEF

Model	Rate Ratio (95% Confidence Interval) p-value		
	CSA vs Negative	CSA vs OSA	OSA vs Negative
Univariate	2.0 (1.6, 2.5) p < 0.0001	1.3 (1.0, 1.5) p = 0.02	1.6 (1.3, 2.0) p < 0.0001
Adjusted	2.0 (1.5, 2.6) p < 0.0001	1.2 (1.0, 1.5) p = 0.05	1.6 (1.3, 2.1) p < 0.0001



European Heart Journal Advance Access published January 29, 2015

European Heart Journal
doi:10.1093/ehj/ehu462

CLINICAL RESEARCH
Heart failure/cardiomyopathy

Sleep disordered breathing and post-discharge mortality in patients with acute heart failure

Rami Khayat^{1,2}, David Jarjoura³, Kyle Porter¹, Angela Sow¹, Jacob Wannemacher¹, Robert Dohar¹, Adam Pleister^{1,2}, and William T. Abraham^{1,2}

¹Department of Cardiology, University of Colorado, Aurora, Colorado, The Rocky Mountain Medical Research Institute, Aurora, Colorado, USA; ²Center for Heart Failure Research, University of Colorado, Aurora, Colorado, USA; ³Department of Biostatistics, University of Colorado, Aurora, Colorado, USA

Received 19th November 2014; accepted 22 December 2014

Background Hospitalizations for heart failure are associated with a high post-discharge risk for mortality. Identification of modifiable predictors of post-discharge mortality during hospitalization may improve outcomes. Sleep disordered breathing (SDB) is the most common comorbidity in heart failure patients.

Design, setting, and participants Prospective cohort study of patients hospitalized with acute heart failure (AHF) in a single academic heart hospital, between January 2007 and December 2010. All patients hospitalized with AHF who have an overnight apnoea-hypnoea test (AHT) $\geq 45\%$ and were not already diagnosed with SDB were the target population.

Main outcomes and measures Patients underwent in-hospital attended polysomnography testing for SDB and were followed for a median of 3 years post-discharge. Mortality was measured using national and state vital statistics databases.


Results During the study period, 1177 hospitalized AHF patients underwent successful sleep testing. Three hundred and forty-four patients (30%) had severe sleep apnoea (CSA $\geq 30\%$), 10% patients had obstructive breathing apnoea (OSA), and 60% had no or minimal SDB (noSDB). Of those, 508 patients survived to discharge and were included in the mortality analysis. Central sleep apnoea was independently associated with mortality. The multivariable hazard ratio (HR) for mortality for CSA vs. noSDB was 1.61 (95% CI 1.1, 2.4, P = 0.02). Obstructive sleep apnoea was also independently associated with mortality with a multivariable HR of 1.53 (CI 1.1, 2.2, P = 0.02). The Cox proportional hazards model adjusted for the following covariates: LVESV, age, BNP, eGFR, creatinine, diabetes, type of cardiomyopathy, comorbid major disease, chronic kidney disease, discharge blood pressure > 110 , hypertension, discharge medication, initial length of stay, admission sodium, haemoglobin, and BUN.

Conclusions This is the largest study to date to evaluate the effect of SDB on post-discharge mortality in patients with AHF. Newly diagnosed CSA and OSA during AHF hospitalizations are independently associated with post-discharge mortality.

Keywords Heart failure • Sleep disordered breathing • Sleep apnoea • Post-discharge mortality



SDB is Independently Associated with Post-discharge Mortality



Khayat et al EHJ 2015



25

Treatment of SDB during ADHF and in the Post-Discharge Period

Pilot RCT Evaluating Treatment of OSA during ADHF; Khayat et al Chest 2009

Baseline Characteristics	Control group (n=23) Mean (SE)	Intervention group (n=23) Mean (SE)	95% CI for the difference
LVEF (%)	25.4 (1.8)	26.3 (1.8)	(-6.1, 4.3)
AHI (events per hour)	33 (3.0)	36 (2.0)	(-11, 5)
BNP	1154 (261)	1117 (259)	(-708, 780)
SBP (mmHg)	110 (4.0)	107 (4.0)	(-8, 14)
DBP (mmHg)	67 (2.0)	66 (2.0)	(-5, 8)
Heart Rate	88 (4.0)	81 (3.0)	(-3, 17)
Creatinine	1.3 (0.08)	1.4 (0.13)	(-0.4, 0.2)
LVEDD	62 (2.0)	64 (2.0)	(-8, 2)
LVEDV	227(18)	235 (20)	(-63, 47)
LVESV	169 (15)	171 (17)	(-48, 44)
Age	58 (3.0)	55 (3.0)	(-5, 11)
BMI (Kg/m ²)	32 (2.0)	35 (3.0)	(-10, 3)
% Male	83 (8.0)	65 (10)	(-9, 44)
% Ischemic cardiomyopathy	78 (9.0)	87 (7.0)	(-32, 14)
% of b-blockers	83 (8.0)	74 (9.0)	(-16, 34)
% of Number ACEI or AII-I	65 (10)	48(11)	(-12, 47)
% Diabetes	54 (11)	61 (10)	(-41, 20)

Effect of In Hospital APAP on Cardiac Function three days post-randomization

	Control	Treatment	Difference (APAP Effects) (p-value)
LVEF			
three days post randomization	25.8	30.4	4.6
			(0.031)
change from base line (Final - Baseline)	-0.2	4.4	
LVESV			
three days post randomization	169	144	-24.8
			(0.0007)
change from base line (Final - Baseline)	3.2	-22.1	
LVEDV			
three days post randomization	228	204	-23.9
			(0.03)
change from base line (Final - Baseline)	2.1	-22	


Khayat et al Chest 2009

Effect of PAP on hemodynamic and neurohumoral measures

Change from baseline	Control	Treatment	Difference (p-value)
Urinary Norepinephrine	-0.003	-0.011	-0.0008 (0.18)
BNP	17	-457	-474 (0.13)
BUN	-2.4	1.6	4.1 (0.18)
Creatinine	-0.03	0.21	-0.24 (0.19)
Systolic BP	-5.2	-6.5	-1.3 (0.78)
Diastolic BP	-1.2	-3	-1.9 (0.6)
Weight	-0.5	-2	-1.5 (0.048)

Khayat et al Chest 2009

Pilot RCT Evaluating the Effect of In-hospital PAP on Discharge LVEF in Patients with ADHF and OSA



Khayat et al Chest 2009
